Scarica l'app Stockscreener
2.655
7.14%
-0.215
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
New Jersey Pharma Co. Shares Positive Pediatric Study - streetwisereports.com
Aquestive completes marketing application for Anaphylm in U.S. - MSN
Aquestive stock gains as Anaphylm NDA completes (AQST:NASDAQ) - Seeking Alpha
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data - Benzinga
Aquestive Therapeutics’ Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating - TipRanks
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film - BioSpace
Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA - TipRanks
Aquestive’s Anaphylm shows promise in pediatric study - Investing.com
Aquestive Therapeutics Announces Positive Topline PK - GlobeNewswire
Revolutionary Allergy Treatment Proves Safe in Children: Game-Changing Alternative to EpiPen Heads to FDA - Stock Titan
Charles Schwab Investment Management Inc. Grows Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World
Aquestive stock falls amid Libervant approval, Anaphylm update - MSN
Bank of New York Mellon Corp Reduces Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy - Seeking Alpha
Aquestive Therapeutics: Not For Me, But Attractive (NASDAQ:AQST) - Seeking Alpha
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark - simplywall.st
What is HC Wainwright’s Estimate for AQST Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for AQST FY2026 Earnings? - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC Wainwright - Defense World
Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Aquestive Therapeutics Advances Product Pipeline and Market Access - TipRanks
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Earnings Call Transcript - Insider Monkey
Buy Rating on Aquestive Therapeutics Driven by Anaphylm’s Regulatory Progress and Strategic Launch Preparations - TipRanks
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings - MSN
Lake Street Capital Lowers Aquestive Therapeutics (NASDAQ:AQST) Price Target to $8.00 - Defense World
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts - Yahoo Finance
Aquestive Therapeutics price target lowered to $4.75 from $5.50 at Alliance Global Partners - TipRanks
New York State Common Retirement Fund Grows Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Aquestive Therapeutics: Strategic Advancements and Financial Strength Underpin Buy Rating - TipRanks
Earnings call transcript: Aquestive Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com UK
Earnings call transcript: Aquestive Therapeutics Q4 2024 misses estimates - Investing.com
Aquestive Therapeutics: Q4 Earnings Snapshot - Midland Daily News
Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates - MSN
Aquestive Therapeutics Q4 Net Loss Widens, Revenue Falls; 2025 Revenue Outlook Issued - Marketscreener.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Aquestive Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics - Nasdaq
Aquestive Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aquestive Therapeutics reports Q4 EPS (19c), consensus (13c) - TipRanks
Aquestive Therapeutics misses Q4 estimates, shares fall By Investing.com - Investing.com South Africa
Aquestive Therapeutics misses Q4 estimates, shares fall - Investing.com India
9.75%
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):